Late last year, a Hong Kong-based Caymans-incorporated company, Zmay Holdings, caught the stem cell fever, plunking down around $40 million (a total of 330 mil HKD) in bonds and equity in a deal for a technology that apparently involves growing various types of human stem cells from ordinary somatic cells by treating them with Chinese herbs like ginseng, angelica and bitter melon, or a dash of deer antler and leech extract if you have them handy. The specifications are strangely quiet on the feng shui conditions under which these processes should be conducted – I’m guessing trade secret. Jokes aside, this looks like another step in the inexorable march of so-called “stem cells” into penumbral territory usually occupied by homeopathy, energy healing and Baron Samedi.
Zmay, whose English website reveals one of its primary business to be funeral services and cemetery management, bought the tech from inventor Xiongbin Lin, through a contorted (to me, anyway) deal involving multiple foreign-registered holding companies and fronts. No mention is made of whether anti-aging customers who die as a result of “stem cell” treatment will get a deal on a headstone and plot of turf.
|Death – the ultimate anti-aging solution|